Rilmenidine hemifumarate iKan 083 is an investigational drug candidate

is an investigational drug candidate for metastatic colorectal cancer

Smiles: O[C@@H]1CCCN[C@H]1CC(=O)CN1C=NC2=CC(Br)=C(Cl)C=C2C1=O

InChiKey: NNACHAUCXXVJSP-UHFFFAOYSA-N

Mono-L-aspartyl chlorin e6

while binding to the low affinity site blocks the channel

Rilmenidine hemifumarate iKan 083 is an investigational drug candidateRilmenidine hemifumarate, an innovative antihypertensive agent, is an orally active, selective I1 imidazoline receptor agonist. Rilmenidine hemifumarate is an alpha 2 adrenoceptor agonist. Rilmenidine hemifumarate induces autophagy. Rilmenidine hemifumarate acts both centrally by reducing sympathetic overactivity and in the kidney by inhibiting the Na+ H+ antiport. Rilmenidine hemifumarate modulates proliferation and stimulates the proapoptotic